Get started
Author

Daniele Bellavia

Observed names: Bellavia, Daniele, D Bellavia, Daniele, Bellavia
Observed institution: University Carlo Cattaneo
ORCID: 0000-0003-1342-5908
Observed ORCID: 0000-0003-1342-5908
OpenAlex ID: A5035251594
A prediction framework for pharmaceutical drug consumption using short time-series
2024 · Francesco Bertolotti, Fabrizio Schettini, et al. · Expert Systems with Applications · 19
The Impact of Automation and Digitalization in Hospital Medication Management: Economic Analysis in the European Countries
2025 · Federico Filippo Orsini, Daniele Bellavia, et al. · Healthcare · 9
PDF
4CPS-005 Evaluating pharmaceutical logistics automated technologies in the hospital setting: a health technology assessment (HTA) approach
2022 · E Foglia, E Garagiola, et al. · European Journal of Hospital Pharmacy · 2
PDF
Correction: Orsini et al. The Impact of Automation and Digitalization in Hospital Medication Management: Economic Analysis in the European Countries. Healthcare 2025, 13, 1604
2026 · Federico Filippo Orsini, Daniele Bellavia, et al. · Healthcare · 1
MSR43 The Use of Safety-Engineered Devices in Preventing Needle-Stick Injuries: A Budget Impact Analysis
2022 · D Bellavia, F Schettini, et al. · Value in Health · 1
PDF
HSD64 Integrating CEUS in Diagnostic Pathways: Evidence of Economic and Organizational Sustainability From the Italian Healthcare System
2025 · Lucrezia Bianca Ferrario, FABRIZIO SCHETTINI, et al. · Value in Health
Optimization in the HIV treatment: economic and organizational impact analysis of Bictegravir/Emtricitabine/Tenofovir Alafenamide
2025 · Lucrezia Ferrario, Barbara Menzaghi, et al. · Global & Regional Health Technology Assessment
Correction: From Clinical to Non-clinical Outcomes in the Treatment of HIV: An Economic and Organizational Impact Assessment
2025 · Lucrezia Ferrario, Barbara Menzaghi, et al. · PharmacoEconomics - Open
PDF
EE214 Economic and Organizational Advantages of Bictegravir/Alafenamide Tenofovir/Emtricitabine for HIV Treatment
2024 · LB Ferrario, B Menzaghi, et al. · Value in Health
HSD15 Biosimilars and Originators: Utilization and Costs in Lombardy Region
2022 · E Foglia, D Bellavia, et al. · Value in Health
PDF
HSD29 Factors Influencing Deprescribing Activities in the Management of Hospitalized Patients in Polytherapy
2022 · E Foglia, LB Ferrario, et al. · Value in Health
MSR32 COVID-19 Beds’ Occupancy and Hospital Complaints: A Predictive Model
2022 · E Foglia, LB Ferrario, et al. · Value in Health
PDF
HTA178 High-Energy Devices and Standard Monopolar/Bipolar Devices: An HTA in the Italian Surgical Setting
2022 · LB Ferrario, F Asperti, et al. · Value in Health
Works count: 15
Citation count: 32
H-index: 2
I10-index: 1
Year
Topic
Type